Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex
Observational
Observational Model: Cohort, Time Perspective: Prospective
Percent of patients remaining adherent to therapy with Arimidex
Every 3 months
No
Zsolt Horvath, M.D., Ph.D.
Principal Investigator
Hungarian National Institute of Oncology
Hungary: National Institute of Pharmacy
NIS-OHU-ARI-2010/1
NCT01081509
March 2010
October 2011
Name | Location |
---|